NCT04412057View on ClinicalTrials.gov

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

December 14, 2020

Study Completion Date

January 19, 2021

Conditions
COVID-19 PneumoniaAcute Lung InjuryARDS
Interventions
DRUG

CERC-002

Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.

DRUG

Placebo

Administered once subcutaneously

Trial Locations (11)

19140

Temple University Hospital, Philadelphia

28304

Carolina Institute for Clinical Research, LLC, Fayetteville

29414

Lowcountry Infectious Diseases, P.A., Charleston

29621

AnMed Health Medical Center, Anderson

33407

Triple O Research Institute, P.A., West Palm Beach

34982

Midway Immunology and Research Center, Ft. Pierce

46845

Parkview Research Center, Fort Wayne

70006

MedPharmics, LLC, Metairie

71103

LSUHSC - Shreveport, Shreveport

78503

BRCR Global Texas, McAllen

92663

Hoag Memorial Hospital, Newport Beach

All Listed Sponsors
lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT04412057 - Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury | Biotech Hunter | Biotech Hunter